The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global mandibular advancement devices market is expected to exhibit a CAGR of 16.1% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Mandibular advancement devices (MADs) are utilized in the non-continuous positive airway pressure (CPAP) therapy to treat obstructive sleep apnea hypopnea syndrome (OSAHS). These devices help prevent upper airway collapse by protruding the mandible forward, altering the jaw and tongue position, and enhancing the rigidity of the airway by increasing the muscle activity of the tongue and other muscles. Besides this, as they improve the upper airway size and reduce the risk of sleep apneas and snoring among patients, MADs are widely recommended by doctors in case of mild OSAHS and CPAP failure.
According to the National Center for Biotechnology Information (NCBI), OSAHS is a serious illness affecting 12% of adults in the United States. This can be accredited to the physical, medical, environmental, genetics, and psychiatric factors. Moreover, as per the Journal of Thoracic Disease, 2018, OSAHS is associated with an increased risk of road traffic accidents and cardiovascular diseases. As most of the patients are undiagnosed, it is posing severe healthcare and economic burden to countries worldwide. As a result, governing agencies of several countries are undertaking initiatives to spread awareness about the ailment and its ill effects if left untreated. Apart from this, the rising geriatric population is also contributing to the growth of the market. Additionally, MADs are widely available in the regular size that requires an initial softening before placing. Semi- and completely customized variants are also available to get a better result. Some of the other factors positively driving the overall sales of MADs include the growing healthcare expenditure, rising usage of oral appliances, and the increasing number of companies venturing into the industry.
IMARC Group provides an analysis of the key trends in each sub-segment of the global mandibular advancement devices market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, application, material type and distribution channel.
Breakup by Product:
Breakup by Application:
Breakup by Material Type:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Advanced Brain Monitoring Inc., Apnea Sciences Corporation, DynaFlex , Erkodent Erich Kopp GmbH, NDX Keller Dental Lab, OSCIMED SA, ResMed, Scheu-Dental GmbH (Armira Partners GmbH & Co KG), SomnoMed, The Aurum Group and Tomed GmbH.
|Base Year of the Analysis||2021|
|Segment Coverage||Product, Application, Material Type, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Advanced Brain Monitoring Inc., Apnea Sciences Corporation, DynaFlex , Erkodent Erich Kopp GmbH, NDX Keller Dental Lab, OSCIMED SA, ResMed, Scheu-Dental GmbH (Armira Partners GmbH & Co KG), SomnoMed, The Aurum Group and Tomed GmbH|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at